PCOS – Medxy AI

Diabetes & Endocrinology news OB/GYN & Women's Health

Unraveling the Complex Interplay of BMI and Inflammation on Assisted Reproductive Outcomes in PCOS Women

By MedXY 10/26/2026

This study reveals bidirectional mediation between BMI and inflammatory markers affecting embryo quality and availability in PCOS women undergoing ART, highlighting BMI's predominant role.

Saroglitazar为PCOS合并MASLD女性的肝脂肪变性治疗带来新希望：一项多中心试验的启示

Diabetes & Endocrinology Gastroenterology news

Saroglitazar Shows Promise in Treating Hepatic Steatosis in Women with PCOS and MASLD: Insights from a Multicenter Trial

By MedXY 10/21/2026

Saroglitazar significantly improves liver fat content, liver enzymes, and lipid profiles in women with PCOS and MASLD, highlighting its potential as a therapeutic option in this underrepresented population.

Diabetes & Endocrinology news Pathology & Lab Medicine

New Consensus on Testosterone Reference Ranges for Females and Children: Outcomes of the 2024 PCOS Challenge–CDC Stakeholder Meeting

By MedXY 09/19/2026

A stakeholder consensus sets a roadmap to develop standardized, age- and sex-specific testosterone reference intervals for women, adolescent girls, and children to improve diagnosis and care for androgen-related disorders.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Unraveling the Role of 11-Oxygenated Androgens in PCOS: Phenotype-Specific Profiles and Treatment Responses

By MedXY 09/02/2026

This article explores how 11-oxygenated androgens differ by PCOS phenotypes and respond to first-line therapies, emphasizing their role in phenotyping and guiding treatment in polycystic ovary syndrome.

Clinical Updates news OB/GYN & Women's Health

Early Life Adversity and Polycystic Ovary Syndrome among North American Pregnancy Planners: A Comprehensive Review

By MedXY 07/01/2026

This review synthesizes current evidence linking adverse childhood experiences with increased risk and features of PCOS, highlighting possible neuroendocrine mechanisms and clinical implications for reproductive health management.

Diabetes & Endocrinology Gastroenterology news

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood

By MedXY 05/28/2026

In the Raine Study, adolescents with both MASLD and PCOS had a substantially worse cardiometabolic profile by age 27 than peers with either condition alone, highlighting a high-risk subgroup that may warrant earlier metabolic surveillance.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Prepregnancy Insulin Resistance and Fertility Outcomes in Women With PCOS

By MedXY 05/26/2026

Higher insulin resistance before pregnancy was linked to poorer ovulation, lower pregnancy and live-birth rates, and more gestational diabetes in women with PCOS. Improving insulin resistance during treatment was associated with better pregnancy outcomes.

news OB/GYN & Women’s Health Pathology & Lab Medicine/Bệnh học

Microbial and Metabolic Correlates of Endometrial Dysfunction in Polycystic Ovary Syndrome: A Translational Study

By MedXY 05/20/2026

This study links PCOS-related miscarriage risk to gut microbiome changes, especially reduced Parabacteroides merdae and higher isoleucine, which may promote endometrial senescence and impair pregnancy outcomes.

Diabetes & Endocrinology news

One-Hour Plasma Glucose: A Vital Predictor of Cardiometabolic Risk in Women with PCOS

By MedXY 03/15/2026

A retrospective study highlights how 1-hour plasma glucose levels can identify early cardiometabolic risks in women with PCOS who appear to have normal blood sugar levels.

Diabetes & Endocrinology news

Elevated MCP1 and FABP4 in Early PCOS Pregnancy: Metabolic Markers Driven by Adiposity Rather Than Disease Status

By MedXY 03/10/2026

A cross-sectional study reveals that while MCP1 and FABP4 are elevated in early pregnancy among women with PCOS, these biomarkers primarily reflect maternal adiposity and do not independently predict adverse outcomes, highlighting the importance of pre-conception weight management.

Clinical Updates Diabetes & Endocrinology news

Undiagnosed Hyperandrogenism in Type 1 Diabetes: Clinical Evidence, Mechanisms, and Screening Implications

By MedXY 12/27/2025

Recent evidence reveals that one in four premenopausal women with Type 1 diabetes (T1D) suffers from undiagnosed androgen excess disorders, primarily the classic PCOS phenotype, necessitating routine screening and a recalibration of reproductive healthcare in diabetic management.

Diabetes & Endocrinology news OB/GYN & Women's Health

One in Four Premenopausal Women with Type 1 Diabetes Faces Undiagnosed Androgen Excess Disorders

By MedXY 12/27/2025

A cross-sectional study reveals that 26% of women with Type 1 Diabetes suffer from undiagnosed androgen excess, primarily PCOS. The findings emphasize the role of iatrogenic hyperinsulinism and advocate for routine screening, especially for those with premenarcheal diabetes onset.

Diabetes & Endocrinology news

PCOS as a Biological Model for Reproductive Longevity: Enhanced Ovarian Reserve and ART Success in Aging Asian Women

By MedXY 12/25/2025

A retrospective study of 1,249 Asian women reveals that those with PCOS maintain superior ovarian reserve and stable cumulative pregnancy rates via ART even after age 36, suggesting PCOS may serve as a biological model for extended reproductive longevity.

Diabetes & Endocrinology news

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

By MedXY 11/17/2025

A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was low due to heterogeneity and risk of bias.

Diabetes & Endocrinology news

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

By MedXY 11/17/2025

Diabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

By MedXY 11/14/2025

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

By MedXY 09/16/2025

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent alone or placebo.

Clinical Updates news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY 09/16/2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

news OB/GYN & Women's Health Specialties

Gut Microbiota and Pregnancy Risks: the Connection in Polycystic Ovary Syndrome

By MedXY 07/29/2025

Scientific findings link imbalances in gut microbiota and metabolic markers to pregnancy complications in women with PCOS.

news OB/GYN & Women's Health Specialties

Exploring Sexual Function in Women with PCOS: Insights from Recent Research

By MedXY 07/28/2025

A systematic review assesses sexual function in women with PCOS, revealing impaired psychosexual function and calling for more diverse and comprehensive studies.